---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-251698"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:43:21.987994+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q3 portfolio receipts up 15% to $735M; raises FY guidance to $2.75-2.8B

## Summary
- Royalty Receipts grew 15% to $732M; Portfolio Receipts $735M, driven by Trelegy, Evrysdi, cystic fibrosis franchise.
- Full-year 2024 Portfolio Receipts guidance raised to $2.75B-$2.8B (from $2.7B-$2.775B); Royalty Receipts growth 11-13%.
- Capital Deployment of ~$1.2B in Q3; acquired synthetic royalties on Niktimvo ($350M) and Yorvipath ($150M).
- Net cash from operations $704M; repurchased ~3M shares for $95M during Q3; cash and equivalents $950M.
- FDA approvals for Cobenfy (schizophrenia), Tremfya (ulcerative colitis), Voranigo (glioma) benefit royalty portfolio.

## SEC filing metadata
- accession: 0001193125-24-251698
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312524251698/0001193125-24-251698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312524251698/d904706d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-251698
- JSON: https://secwatch.observer/filing/0001193125-24-251698.json
- Plain text: https://secwatch.observer/filing/0001193125-24-251698.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.